WaveMan · Form 4
RA Capital Nexus Fund II, L.P. insider trades
> Search tickers & screens ⌘K
LIVE

RA Capital Nexus Fund II, L.P. insider trades

RA Capital Nexus Fund II, L.P. has filed 17 Form 4s with the SEC that we hold, for AN2 Therapeutics, Inc. (ANTX) (10% owner), Janux Therapeutics, Inc. (JANX) (Director, 10% owner), Acrivon Therapeutics, Inc. (ACRV) (Director, 10% owner) and Acumen Pharmaceuticals, Inc. (ABOS) (Director, 10% owner), among 10 companies in all. Across all of them we count 19 purchases worth $98.8M and 0 sales worth $0 reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a purchase of 3,004,782 shares of Climb Bio, Inc. worth $37.6M, dated 2021-08-12. The first filing on our record is dated 2021-08-16 and the latest 2026-06-12.

AN2 Therapeutics, Inc. (ANTX)

10% owner · 3 filings · 5 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-06-13P, purchase reported on Form 420,000$158.0K2022-06-15
2022-06-14P, purchase reported on Form 461,424$489.5K2022-06-15
2022-07-26P, purchase reported on Form 414,938$115.2K2022-07-28
2022-07-27P, purchase reported on Form 48,281$65.5K2022-07-28
2023-08-18P, purchase reported on Form 41,777,778$16.0M2023-08-22

Janux Therapeutics, Inc. (JANX)

Director, 10% owner · 3 filings · 1 purchase or sale
Trade dateCodeSharesValue as filedFiled
2023-07-19P, purchase reported on Form 4495,008$6.2M2023-07-21

Acrivon Therapeutics, Inc. (ACRV)

Director, 10% owner · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Acumen Pharmaceuticals, Inc. (ABOS)

Director, 10% owner · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Climb Bio, Inc. (ELYM)

Director, 10% owner · 2 filings · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-08-12P, purchase reported on Form 43,004,782$37.6M2021-08-16
2021-08-12P, purchase reported on Form 4195,218$2.4M2021-08-16

Cytek Biosciences, Inc. (CTKB)

Director · 1 filing · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-02-23P, purchase reported on Form 4214,922$2.9M2022-02-25
2022-02-24P, purchase reported on Form 4186,467$2.4M2022-02-25
2022-02-25P, purchase reported on Form 418,991$246.7K2022-02-25

DICE

Director, 10% owner · 1 filing · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-03-28P, purchase reported on Form 4246,779$7.2M2023-03-30
2023-03-29P, purchase reported on Form 466,369$1.9M2023-03-30
2023-03-30P, purchase reported on Form 4195,997$5.6M2023-03-30

LENZ Therapeutics, Inc. (LENZ)

Director, 10% owner · 1 filing · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2024-03-21P, purchase reported on Form 464,971$976.5K2024-03-25
2024-03-21P, purchase reported on Form 4933,038$14.0M2024-03-25

PepGen Inc. (PEPG)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Werewolf Therapeutics, Inc. (HOWL)

Director, 10% owner · 1 filing · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2025-05-12P, purchase reported on Form 4320,913$276.0K2025-05-14
2025-05-13P, purchase reported on Form 452,974$51.9K2025-05-14
2025-05-14P, purchase reported on Form 4162,539$159.3K2025-05-14
Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1825376) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms